FibroGen Inc (FGEN) - Net Assets
Based on the latest financial reports, FibroGen Inc (FGEN) has net assets worth $17.48 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($137.01 Million) and total liabilities ($119.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FibroGen Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.48 Million |
| % of Total Assets | 12.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | -141.6% |
| 10-Year Change | -193.3% |
| Growth Volatility | 89.92 |
FibroGen Inc - Net Assets Trend (2012–2024)
This chart illustrates how FibroGen Inc's net assets have evolved over time, based on quarterly financial data. Also explore FibroGen Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for FibroGen Inc (2012–2024)
The table below shows the annual net assets of FibroGen Inc from 2012 to 2024. For live valuation and market cap data, see FibroGen Inc (FGEN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-183.63 Million | -13.22% |
| 2023-12-31 | $-162.20 Million | -10859.39% |
| 2022-12-31 | $-1.48 Million | -100.65% |
| 2021-12-31 | $229.11 Million | -48.10% |
| 2020-12-31 | $441.45 Million | -17.55% |
| 2019-12-31 | $535.41 Million | +1.31% |
| 2018-12-31 | $528.47 Million | -9.27% |
| 2017-12-31 | $582.45 Million | +232.62% |
| 2016-12-31 | $175.11 Million | -11.03% |
| 2015-12-31 | $196.82 Million | -18.22% |
| 2014-12-31 | $240.68 Million | +123.67% |
| 2013-12-31 | $107.60 Million | -11.93% |
| 2012-12-31 | $122.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to FibroGen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 164166300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.01 Million | % |
| Other Comprehensive Income | $-5.73 Million | % |
| Other Components | $1.67 Billion | % |
| Total Equity | $-225.60 Million | 100.00% |
FibroGen Inc Competitors by Market Cap
The table below lists competitors of FibroGen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
$37.31 Million |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
$37.31 Million |
|
NextTrip Inc
NASDAQ:NTRP
|
$37.32 Million |
|
Pharmx Technologies Ltd
AU:PHX
|
$37.33 Million |
|
IL&FS Engineering and Construction Company Limited
NSE:IL&FSENGG
|
$37.29 Million |
|
Native Mineral Resources Holdings Ltd
AU:NMR
|
$37.29 Million |
|
Kirklands Inc
NASDAQ:KIRK
|
$37.29 Million |
|
Farm Price Holdings Berhad
KLSE:0304
|
$37.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FibroGen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -204,166,000 to -225,601,999, a change of -21,435,999.
- Net loss of 47,579,000 reduced equity.
- Dividend payments of 2,230,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,143,001.
- Other factors increased equity by 27,230,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-47.58 Million | -21.09% |
| Dividends Paid | $2.23 Million | -0.99% |
| Other Comprehensive Income | $1.14 Million | +0.51% |
| Other Changes | $27.23 Million | +12.07% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares FibroGen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $7.17 | $9.22 | x |
| 2013-12-31 | $1.69 | $9.22 | x |
| 2014-12-31 | $3.85 | $9.22 | x |
| 2015-12-31 | $2.94 | $9.22 | x |
| 2016-12-31 | $2.48 | $9.22 | x |
| 2017-12-31 | $7.72 | $9.22 | x |
| 2018-12-31 | $6.06 | $9.22 | x |
| 2019-12-31 | $5.96 | $9.22 | x |
| 2020-12-31 | $4.70 | $9.22 | x |
| 2021-12-31 | $2.26 | $9.22 | x |
| 2022-12-31 | $-0.23 | $9.22 | x |
| 2023-12-31 | $-2.10 | $9.22 | x |
| 2024-12-31 | $-2.26 | $9.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FibroGen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -160.63%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-31.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -34.47% | -49.40% | 0.25x | 2.81x | $-42.02 Million |
| 2013 | -18.74% | -14.63% | 0.34x | 3.72x | $-22.92 Million |
| 2014 | -26.88% | -43.24% | 0.28x | 2.18x | $-81.64 Million |
| 2015 | -48.31% | -47.44% | 0.38x | 2.65x | $-103.53 Million |
| 2016 | -39.58% | -34.35% | 0.38x | 3.01x | $-77.26 Million |
| 2017 | -22.41% | -100.43% | 0.14x | 1.60x | $-182.52 Million |
| 2018 | -16.97% | -40.58% | 0.24x | 1.73x | $-137.34 Million |
| 2019 | -14.91% | -30.00% | 0.30x | 1.66x | $-128.58 Million |
| 2020 | -44.84% | -107.36% | 0.21x | 1.96x | $-231.51 Million |
| 2021 | -139.15% | -123.68% | 0.30x | 3.70x | $-311.94 Million |
| 2022 | 0.00% | -208.66% | 0.23x | 0.00x | $-291.51 Million |
| 2023 | 0.00% | -607.29% | 0.11x | 0.00x | $-263.82 Million |
| 2024 | 0.00% | -160.63% | 0.14x | 0.00x | $-25.02 Million |
Industry Comparison
This section compares FibroGen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FibroGen Inc (FGEN) | $17.48 Million | -34.47% | 6.84x | $37.30 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more